There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Changes in hormones, lipids and symptoms after the administration of a commercial preparation with dehydroepiandrosterone in postmenopausal women.
Dehydroepi and rosterone ( DHEA ) is an adrenal and rogen precursor of sex steroids with effects on a variety of physiological events [ 1 ] . DHEA and its sulfate ( DHEAS ) , as well as and rostendione , have minimal and rogenic activity [ 2 ] . It has been reported that serum levels of DHEA and DHEA-S substantially decrease with age , and experimental studies have demonstrated benefit with DHEA substitution at physiologic doses [ 3 ] . DHEA and DHEA-S are abundant in the circulation . DHEA-S accounts for more than 99 % of the steroid in the serum , with less than 1 % of free DHEA . Their main actions have been related to cellular control , immunoregulation , obesity and lipid metabolism [ 2 ] . Estrogen and and rogen replacement therapy date s to 1941 , when Geist and Salmon used and rogen therapy to treat climacteric symptoms [ 4 ] . DHEA has also been used as part of hormone therapy . In a study in which women from 60 to 70 years age received  DHEA  , a significant increase was observed in bone mineral density at the hip . This was followed by an increase in serum osteocalcin ( a bone formation marker ) , which was supposed to be due to DHEA and rogenic action . These results suggest that DHEA can be useful in the prevention and treatment of osteoporosis [ 5 ] . In another study , DHEA was given in a dose of 50 mg/day for 6 months to men and women aged 40 to 70 years . No changes were observed in estrone ( E ) and estradiol ( E2 ) serum levels in either sex . In women , there was a decrease in high-density lipoprotein cholesterol ( HDL-C ) levels without changes in the other lipids . Insulin sensitivity and mean body fat were not modified , and an increase in subjective physical well-being was cl aim ed in 67 % of men and in 84 % of women [ 6 ] . When DHEA was applied percutaneously in women from 60 to 70 years age for 12 months , no changes were observed in body weight . However , there was a 3.8 % decrease of body fat and an increase of 3.5 % in the muscular mass at the femoral level . HDL-C levels decreased 8 % , but the HDL-C/total cholesterol ratio did not change due to a parallel decrease of total cholesterol [ 7 ] . It then appears that the literature is controversial about DHEA effects . Commercial DHEA formulations are frequently used in Mexico , as in other countries . Therefore , the objective of this study was to evaluate a formulation of DHEA ( Siscelar plus  ) , commercially available in Mexico , on hormone and lipid levels and on climacteric symptoms after administration to postmenopausal women
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .